Precision medicine has revolutionised cancer treatments; however, actionable biomarkers
remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) …

The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …

Highlights•mCRC patients' survival outcomes pose major treatment challenge for
oncologists.•Personalized medicine is an evolving approach for cancer management …

Colorectal cancer (CRC) is one of the most common human malignant diseases and the
second leading cause of cancer-related deaths worldwide. The treatment of advanced CRC …

Purpose Uncertainty exists regarding comparative effectiveness of cetuximab versus
bevacizumab in metastatic colorectal cancer (mCRC). We conducted a retrospective head-to …

3513 Background: Encorafenib+ binimetinib+ cetuximab (enco/bini/cetux; triplet) and enco+
cetux (doublet) regimens improved overall survival and objective response rate vs standard …

In metastatic colorectal cancer (mCRC), an improved understanding of the underlying
pathology and molecular biology has successfully merged with advances in diagnostic …

Background Although bevacizumab is an important treatment for metastatic colorectal
cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations …

4068 Background: KRAS oncogene mutation status is predictive of efficacy of cetuximab
alone or combined with chemotherapy (CT) in mCRC. Previous data from the phase III …

The treatment of metastatic colorectal cancer (mCRC) has evolved significantly over the past
10 years. For nearly 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) was the only agent …